Showing 1131-1140 of 9871 results for "".
MomGenes, Sernivo Approval, Industry Roundup
https://practicaldermatology.com/topics/psoriasis/dermwiretv-momgenes-sernivo-approval-industry-roundup/18613/In this edition of DermWireTV, from the editors of DermWire.com and Practical Dermatology® magazine, new research gives an up-close-and-personal view of how antiperspirant affects our microbiome. Galderma's new MomGenes campaign aims to change the way mothers and daughters talk about facial aging. TLaser Techniques: What’s Hot
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-techniques-what-rsquo-s-hot/19146/Joel L. Cohen, MD, discusses the use of devices for fat rejuvenation techniques with Mat Avram, MD, Director of Massachusetts General Hospital Laser & Cosmetic Center in Boston. Dr. Avram describes how speaking with colleagues and doing one's homework will further assist in choosing the proper dAn Excellent Networking Opportunity: DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/an-excellent-networking-opportunity-derm2021/19963/From opportunities to connect and network with other NPs and PAs to going to sessions presented by some of her favorite dermatologists, such as Ted Rosen, MD, to learn about what’s in the pipeline and coming to market soon, Leigh Ann Pansch, MSN, FNP-BC, DCNP is excited to attend the DERM2021 NP/PAThings You Must Do to Improve Your Dermatology Website
https://practicaldermatology.com/topics/practice-management/improvewebsite/19552/Your website acts as the digital face of your dermatology practice. While the nitty-gritty of the actual website may vary widely due to a host of factors, there are some basic essentials that no dermatology website can do without. In This Ekwa Marketing video, we discuss four such absolute essentialApproval for Evolus; Remembering Vic Narurkar, MD
https://practicaldermatology.com/topics/practice-management/dermwiretv-approval-for-evolus-remembering-vic-narurkar-md/19553/The FDA has approved Jeuveau, the lead product from Evolus, Inc. David Moatazedi, President and CEO of Evolus, and Michael Jafar, Chief Marketing Officer at Evolus, comment on market potential for the new product.Twenty-eight percent of physicians say the prior authorization process required by healHow to Use Email Effectively to Build Client Loyalty
https://practicaldermatology.com/topics/practice-management/email-loyalty/18218/Using email effectively can help you encourage client loyalty as well as client satisfaction. This Ekwa Marketing video explains how you can do this to optimize client experience and motivate clients to return.Google Webmaster Tools
https://practicaldermatology.com/topics/practice-management/google-webmaster-tools/18285/Google encourages online marketing teams and website owners to use organic, genuine methods to achieve more search engine visibility for their websites. This Ekwa Marketing video explains how Webmaster Tools by Google makes this easier, by helping dermatology website marketers to meet and exceed theTwo Launches from Cutera, AmSpa Projections
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-two-launches-from-cutera-amspa-projections/18356/Cutera introduces two new devices to its laser and energy-based device offerings: Juliet laser represents Cutera's first entry into the women's health segment of the aesthetics market; Secret RF is a new fractional radio frequency microneedling device that effectively remodels collagen, improves milHad Your Fill?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/had-your-fill/18531/If the US filler market seems robust, you should see what's available outside the US, says Hassan Galadari, MD. He provides a global perspective on fillers with a focus on up-and-coming products, the importance of understanding anatomy, and advances in recognizing and treating complications.The Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market avail